Adalimumab

Red

Brand Name(s):Humira , Neotigason
AMGEVITA
Hyrimoz
Imraldi
Hulio

Indication:Psoriasis – moderate to severe chronic plaque

Rationale:1,2,3,8

Considered:Oct-07

Review Date:Nov-23

Comments:
NICE TA 392 Adalimumab for treating moderate to severe hidradenitis suppurativa
June 2016
…………………………
MHRA -Drug Safety Update
Tumour necrosis factor alpha inhibitors: risk of tuberculosis further information at:
http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON404195
April 14